Shah, Nirav N.
Medical College of Wisconsin
4 papers on CoChatORCID 0000-0002-4336-1071
Most cited papers
- Verified
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Shah, N. N., Johnson, B. D., Schneider, D., Zhu, F., Szabo, A., Keever-Taylor, C. A., Krueger, W., Worden, A. A., Kadan, M. J., Yim, S., et al. (2020) · Nature Medicine
CAR-T cell therapy researchImmunotherapy and Immune Responses
Cited by 468
- Verified
Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center
Zhu, F., Shah, N., Xu, H., Schneider, D., Orentas, R., Dropulic, B., Hari, P., & Keever-Taylor, C. A. (2018) · Cytotherapy
CAR-T cell therapy researchImmunotherapy and Immune Responses
Cited by 120
- Verified
Improving the Safety of Oral Chemotherapy at an Academic Medical Center
Shah, N. N., Casella, E., Capozzi, D., McGettigan, S., Gangadhar, T. C., Schuchter, L., & Myers, J. S. (2016) · Journal of Oncology Practice
Pharmacy and Medical PracticesPharmaceutical Practices and Patient Outcomes
Cited by 33
- Verified
Chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia.
Badar, T., & Shah, N. N. (2020) · Current Treatment Options in Oncology
CAR-T cell therapy researchAcute Lymphoblastic Leukemia research
Cited by 27
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free